Shuttle Pharmaceuticals Holdings IncNASDAQ:SHPHNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1600
- TODAY'S CHANGE (%)-0.0100 (-0.8547%)
- Bid / Lots1.1800/ 27
- Ask / Lots1.2000/ 1
- Open / Previous Close1.1800 / 1.1700
- Day Range
- 52 Week Range
- Volume81,887
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SHPH |
|---|---|---|
| 09:32 ET | 2374 | 1.18 |
| 09:35 ET | 20649 | 1.18 |
| 09:42 ET | 254 | 1.1885 |
| 09:44 ET | 100 | 1.1804 |
| 09:48 ET | 600 | 1.1802 |
| 09:50 ET | 2339 | 1.1819 |
| 10:04 ET | 293 | 1.18 |
| 10:09 ET | 149 | 1.1896 |
| 10:15 ET | 700 | 1.1803 |
| 10:18 ET | 125 | 1.185 |
| 10:20 ET | 900 | 1.1803 |
| 10:29 ET | 600 | 1.185 |
| 10:31 ET | 500 | 1.1896 |
| 10:38 ET | 200 | 1.19 |
| 10:40 ET | 4500 | 1.1801 |
| 10:42 ET | 2515 | 1.18 |
| 11:03 ET | 100 | 1.1699 |
| 11:05 ET | 400 | 1.165 |
| 11:07 ET | 2100 | 1.16 |
| 11:09 ET | 200 | 1.1699 |
| 11:20 ET | 200 | 1.1645 |
| 11:23 ET | 100 | 1.1604 |
| 11:27 ET | 170 | 1.165 |
| 11:32 ET | 1300 | 1.1501 |
| 11:34 ET | 500 | 1.1511 |
| 11:41 ET | 200 | 1.16 |
| 12:24 ET | 100 | 1.16 |
| 12:32 ET | 300 | 1.155 |
| 12:37 ET | 1096 | 1.17 |
| 12:42 ET | 500 | 1.1618 |
| 12:44 ET | 200 | 1.1695 |
| 12:53 ET | 300 | 1.1585 |
| 01:26 ET | 100 | 1.15 |
| 01:29 ET | 100 | 1.15 |
| 01:47 ET | 1000 | 1.1558 |
| 01:51 ET | 4200 | 1.16 |
| 01:54 ET | 100 | 1.155 |
| 02:02 ET | 3000 | 1.1502 |
| 02:12 ET | 122 | 1.1511 |
| 02:16 ET | 100 | 1.155 |
| 02:20 ET | 900 | 1.16 |
| 02:30 ET | 100 | 1.1554 |
| 02:45 ET | 700 | 1.1514 |
| 02:48 ET | 300 | 1.1554 |
| 02:52 ET | 1000 | 1.1597 |
| 02:54 ET | 400 | 1.16 |
| 03:08 ET | 100 | 1.16 |
| 03:26 ET | 500 | 1.155 |
| 03:28 ET | 500 | 1.1507 |
| 03:35 ET | 500 | 1.1594 |
| 03:37 ET | 500 | 1.1508 |
| 03:50 ET | 500 | 1.1543 |
| 03:51 ET | 550 | 1.155 |
| 03:53 ET | 3647 | 1.165 |
| 03:57 ET | 1100 | 1.1605 |
| 04:00 ET | 7702 | 1.16 |
Oct 29, 2024
*DJ Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules, from 9:15PM ET on Tuesday Oct 29, 2024 by Dow Jones
9:15PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules, from 9:05PM ET on Tuesday Oct 29, 2024 by Dow Jones
9:05PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharma Pays Off Senior Secured Convertible Note, from 4:05PM ET on Tuesday Oct 29, 2024 by Dow Jones
4:05PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma, from 9:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
9:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
Oct 28, 2024
DJ Shuttle Pharmaceuticals Shares Rise 63% on Drug-Study Site Update, from 6:50PM ET on Monday Oct 28, 2024 by Dow Jones
6:50PM ET on Monday Oct 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shuttle Pharmaceuticals Holdings Inc | 3.9M | -0.1x | --- |
Processa Pharmaceuticals Inc | 3.6M | -0.2x | --- |
Eastgate Biotech Corp | 3.2M | -0.9x | --- |
Psyence Biomedical Ltd | 3.1M | -1.7x | --- |
Titan Pharmaceuticals Inc | 3.8M | -0.6x | --- |
AgriFORCE Growing Systems Ltd | 5.5M | 0.0x | --- |
Company Information
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
Contact Information
- Headquarters
- 401 Professional Drive, Suite 260GAITHERSBURG, MD, United States 20879
- Phone
- 240-403-4212
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Anatoly Dritschilo
- President, Chief Operating Officer
- Peter Dritschilo
- Chief Financial Officer
- Timothy Lorber
- Chief Scientific Officer - Biology
- Mira Jung
- Chief Medical Officer, Chief Clinical Officer
- Tyvin Rich
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-10.29 |
Book Value | $2.02 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
